A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia.

Abstract

This study characterized the pharmacokinetics, safety, and tolerability of Risperidone ISM, a new long-acting intramuscular formulation, for monthly administration without oral supplementation. Patients with schizophrenia received multiple intramuscular injections of 75 mg in the gluteal or deltoid muscle at 28-day intervals. Of the 70 randomized patients… (More)
DOI: 10.1097/YIC.0000000000000203

Topics

Cite this paper

@article{Carabias2018API, title={A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia.}, author={Lourdes A Carabias and Jordi Llaud{\'o} and Ignacio Ayani and Javier Mart{\'i}nez and Robert E. Litman and Ib{\'o}n Gutierro}, journal={International clinical psychopharmacology}, year={2018}, volume={33 2}, pages={79-87} }